4	
1	
2	
3	
-	
4 5	Comparison of a Target Trial Emulation Framework to Cox Regression to Estimate the Effect of Corticosteroids on COVID-19 Mortality
6	
7	Katherine L. Hoffman, MS ¹
8	Edward J. Schenck, MD, MS^2
9	Michael J. Satlin, MD ³
10	William Whalen, MD, MS ² ,
11	Di Pan, MD, MS^2
12	Nicholas Williams, MPH ⁴
13	Iván Díaz, PhD^1
14	
15	¹ Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
16 17	² Division of Pulmonary and Critical Care, Department of Medicine, Weill Cornell Medicine, New York, NY. ³ Division of Infactious Disease, Department of Medicine, Weill Cornell Medicine, New York, NY.
17 18	⁴ Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
	_ · F
19	August 9, 2022
20	
20 21	
22	
23	
24	
25 26	
20 27	
28	
29	
30	
31	2,993 words
32	
33	
34	
35	

36

Key Points

37 Question: How do modern methods for causal inference compare to approaches common in the 38 clinical literature when estimating the effect of corticosteroids on mortality for moderate-to-39 severe coronavirus disease 2019 (COVID-19) patients? Findings: In an analysis using retrospective data for 3,298 hospitalized COVID-19 patients, 40 41 target trial emulation using a doubly robust estimation procedure successfully recovers a 42 randomized controlled trial (RCT) meta-analysis benchmark. In contrast, analytic approaches 43 common in the clinical research literature generally cannot recover the benchmark. 44 **Meaning:** Clinical research based on observational data can unveil true causal relations. 45 However, the correctness of these effect estimates requires designing and analyzing the data 46 based on principles which are different from the current standard in clinical research. Widespread 47 communication and adoption of these analytical techniques are of high importance for the 48 improvement of clinical research.

5	0
-	~

51

Abstract

52	Importance: Communication and adoption of modern study design and analytical techniques is
53	of high importance for the improvement of clinical research from observational data.
54	Objective: To compare (1) a modern method for causal inference including a target trial
55	emulation framework and doubly robust estimation to (2) approaches common in the clinical
56	literature such as Cox proportional hazards models. To do this, we estimate the effect of
57	corticosteroids on mortality for moderate-to-severe coronavirus disease 2019 (COVID-19)
58	patients. We use the World Health Organization's (WHO) meta-analysis of corticosteroid
59	randomized controlled trials (RCTs) as a benchmark.
60	Design: Retrospective cohort study using longitudinal electronic health record data for 28 days
61	from time of hospitalization.
62	Settings: Multi-center New York City hospital system.
63	Participants: Adult patients hospitalized between March 1-May 15, 2020 with COVID-19 and
64	not on corticosteroids for chronic use.
65	Intervention: Corticosteroid exposure defined as >0.5mg/kg methylprednisolone equivalent in a
66	24-hour period. For target trial emulation, interventions are (1) corticosteroids for six days if and
67	when patient meets criteria for severe hypoxia and (2) no corticosteroids. For approaches
68	common in clinical literature, treatment definitions used for variables in Cox regression models
69	vary by study design (no time frame, one-, and five-days from time of severe hypoxia).
70	Main outcome: 28-day mortality from time of hospitalization.

mulation
25.7%
lds ratio
research
ue causal
study and
linical

86 Introduction

Observational databases are invaluable resources when randomized controlled trials (RCTs) are
infeasible or unavailable. However, the correctness of the conclusions gleaned from analyses of
observational data hinges on the careful consideration of study design principles and choice of
estimation methodology.¹⁻⁴

91 In this paper we contrast the use of target trial emulation using contemporary causal inference 92 methods with various traditional analytical approaches using Cox regression. While most 93 epidemiologists and statisticians agree on the importance of a well-defined exposure, outcome, 94 and population of interest, the two strategies we compare differ significantly in the subsequent 95 steps to choose a research question and data analysis method.

96 In the traditional approach to clinical research, the analysis proceeds by postulating a 97 regression model according to the type of data available. For example, when faced with a time-98 to-event outcome, researchers automatically fit a Cox regression model (often due to limitations 99 in knowledge, time, or software capabilities). The coefficients of the regression model are then 100 used to answer to the clinical question of interest. We refer to this approach as a "model-first" 101 approach, due to the primacy of the regression model.

A model-first approach induces multiple problems for the estimation of causal effects.⁵ First, regression coefficients often do not represent quantities of primary scientific interest or welldefined causal effects.⁶ Second, assumptions such as the proportional hazards assumption used in Cox models are rarely correct in medical research, since hazards cannot be proportional when a treatment effect changes over time.⁷ Third, regression models cannot correctly handle timedependent feedback between confounders, treatment, and the outcome.¹ Fourth, the model-first approach yields a tendency to interpret all coefficients in the model; a problem known as the

Table 2 fallacy.⁸ Lastly, model-first approaches fail to account for the variance induced during
 model selection, thereby leading to incorrect statistical conclusions.⁹

111 Recent developments in the causal inference literature provide researchers with a number of tools to alleviate the aforementioned biases. Frameworks such as the target trial emulation¹⁰ and 112 roadmap for causal inference¹¹ allow researchers to proceed with a *question-first* approach. 113 114 Instead of defaulting to effect measures provided by regression models, a question-first approach 115 begins by defining a hypothetical target trial and subsequent target of inference that answers the 116 scientific question of interest. This is the so-called estimand, or quantity to be estimated. After 117 the estimated is chosen, researchers have the freedom to select an estimation technique which 118 mitigates model misspecification biases. Incorporating these principles can help clarify the 119 research question, determine study eligibility requirements, identify enrollment and follow-up times, decide whether sufficient confounder data are available, increase the likelihood of 120 obtaining a correct estimate, and more.^{12,13} 121

In this study, we compare a question-first approach against multiple model-first approaches 122 123 for causal inference. Our case study is the effect of corticosteroids on mortality for moderate-to-124 severe COVID-19 patients using a retrospective cohort of patients at NewYork-Presbyterian 125 Hospital (NYPH) during Spring 2020. Lack of guidance for clinical practice at the beginning of 126 the pandemic meant that high variability existed in the administration and timing of 127 corticosteroids (eFigure 1). Provider practice variability aids in the estimation of causal effects by 128 yielding datasets with adequate natural experimentation, but the resulting complex longitudinal 129 treatment patterns complicate study design and analytical methods. This observational dataset 130 together with results from numerous RCTs on corticosteroids provides a unique opportunity to

131	benchmark	design and	analysis	methods.	We t	benchmark	our target	trial	emulation	results	against
-----	-----------	------------	----------	----------	------	-----------	------------	-------	-----------	---------	---------

132 effect measures obtained in the World Health Organization (WHO)'s RCT meta-analysis.¹⁴

133 Methods

- 134 This study was designed in April 2020, prior to the results of corticosteroid RCTs and resulting
- 135 clinical guidance. It was approved by the Institutional Review Board at Weill Cornell Medicine
- 136 with a waiver of informed consent (no. 20-04021909). This report follows the Strengthening the
- 137 Reporting of Observational Studies in Epidemiology (STROBE) guidelines.¹⁵

138

139 Hypothetical target trial

- 140 **Question**
- 141 What is the effect of a treatment regime of corticosteroids administered under the clinical
- 142 indication of severe hypoxia on mortality for COVID-19 hospitalized patients?

143 **Population**

144 Inclusion criteria is adult COVID-19 positive patients who were admitted to NYPH's Cornell,

145 Lower Manhattan, or Queens locations. Cases are confirmed through reverse-transcriptase-

- 146 polymerase chain-reaction assays performed on nasopharyngeal swab specimens. The tests are
- 147 obtained upon hospital admission, i.e., at the same time of eligibility and time zero. Patients who
- 148 have chronic use of corticosteroids prior to hospitalization or who are transferred into NYPH
- 149 from an outside hospital are excluded.

150 Hypothetical treatment regime

- 151 Patients would be randomized on their first day of hospitalization to receive either (1)standard of
- 152 care therapy (without corticosteroids) or (2)standard of care plus a corticosteroid regimen to be
- administered if and when criteria for severe hypoxia are met. The corticosteroid dosage is a
- 154 minimum of 0.5 mg/kg body weight of methylprednisolone equivalent per 24-hour period and
- the duration of therapy is six days.¹⁶ Corticosteroids include prednisone, prednisolone,
- 156 methylprednisolone, hydrocortisone, and dexamethasone and choice of drug is at the attending
- 157 physician's discretion. Severe hypoxia is defined as the initiation of high-flow nasal cannula,
- venti-mask, noninvasive or invasive mechanical ventilation, or an oxygen saturation of <93%
- after the patient is on 6 Liters of supplemental oxygen via nasal cannula.

160 Outcome and estimand

161 The primary outcome would be 28-day mortality from time of randomization. The contrast of 162 interest is the 28-day mortality rate difference comparing actual receipt of the two treatment 163 regimes (i.e., the per-protocol effect).

164 Data analysis plan

A hypothetical trial can assume no loss-to-follow-up. Under perfect compliance we would
analyze the difference in proportion of patients who experienced the outcome between the two
treatment regimes.

168 Emulation using observational data

169 Data source and cohort

The target trial emulation uses retrospective data from patients who meet the hypothetical trial's
eligibility criteria March 1-May 15, 2020. Demographic, comorbidity, and outcome data were
manually abstracted by trained medical professionals into a secure REDCap database.¹⁷ These
were supplemented with an internal COVID data repository housing laboratory, procedure,
medication, and flowsheet data documented during standard care.¹⁸ Patients are followed for 28
days from hospitalization and lost to follow-up by discharge or transfer to an external hospital
system.

177 Treatment regimes and measurement

To emulate the target trial corticosteroid treatment regime, we estimate the effect of a
hypothetical dynamic treatment regime,¹⁹ whereby each patient is administered six days of
corticosteroids if and when they meet severe hypoxia criteria. This dynamic regime is contrasted
with a static regime where patients never receive corticosteroids.

We measure severe hypoxia using vital signs and flowsheet data and define it in the same way as our target trial. We measure corticosteroid exposure using the medication administration record. We compute cumulative mg/kg dosing of corticosteroids over rolling 24-hour windows, and if a patient received >0.5 mg/kg methylprednisolone equivalent, they are denoted as having corticosteroids exposure that day.

187 Since patients in the observed data are subject to loss-to-follow-up, emulating the trial with 188 observational data requires conceptualizing a hypothetical world where all patients are observed 189 through 28 days. Effects in this hypothetical world can be estimated using observed patient data

under assumptions articulated in the *Data Analysis* section. An illustration of the treatmentregimes as they relate to the observed data are shown in Figure 1.

192 Confounding

193 In contrast to the hypothetical trial, treatment assignment in the observational study is not

194 randomized and depends on physiological characteristics of each patient. We address

195 confounding in our emulation by adjustment for confounders during data analysis. A set of

196 confounders deemed sufficient for adjustment was determined through the expertise of a team of

197 pulmonologists, intensivists, and microbiologists.

198 Baseline confounders include socio-demographics, Body Mass Index (BMI), comorbidities,

and hospital admission location. Time-dependent confounders include vital signs, laboratory

200 results, co-treatments, and mode of respiratory support. The measurement process (i.e., whether a

201 clinician decided to measure these variables) is also an important confounder included in the

analysis. Details of confounders are provided in eMethods. Figure 2 summarizes the relationship

between confounders, treatment, and outcomes in the form of a Directed Acyclic Graph.

204 Outcome and estimand

Our estimand of interest is the difference in 28-day mortality rates in a hypothetical world where we had implemented the two different corticosteroid treatment regimes, as well as an intervention to prevent loss-to-follow-up. Under the assumption that treatment and loss-tofollow-up each day are randomized conditional on the baseline and time-dependent confounders, this estimand is identifiable by a longitudinal g-computation formula.²⁰ It is important to emphasize that conditional randomization is a key assumption without which the target

emulation may fail. This g-formula will be our estimand of interest, but we note that it is not theonly possible identification strategy (see eMethods).

213 Data analysis plan

When using the g-formula to identify causal effects, correct emulation of a target trial requires proper adjustment for measured confounding. It is important to use estimation methods capable of fitting the data using flexible mathematical relationships so that confounding is appropriately removed, especially when the number of baseline and time-dependent confounders is large.

Methods to estimate the g-computation formula (e.g., inverse probability weighting (IPW), 219 220 parametric g-formula, targeted minimum loss-based estimators (TMLE), sequentially doubly robust estimators (SDR), etc.) 21,22 rely on two kinds of mathematical models: (i) the outcome as a 221 222 function of the time-dependent confounders, and (ii) treatment as a function of time-dependent confounders. Methods that use only one of these models are often called *singly robust*, because 223 224 their correctness relies on the ability to correctly specify one of the models (e.g., IPW relies on 225 estimating treatment models correctly). Methods that use both of these models are often called 226 doubly robust, because they remain correct under misspecification of one of the two models. 227 Furthermore, doubly robust estimators such as TMLE and SDR allow the use of machine learning to flexibly fit relevant treatment and outcome regressions.^{23,24} This is desirable because 228 229 these regression functions might include complex relationships, and capturing those relationships 230 is not possible using simpler regression such as the Cox model.²⁵

The primary analysis is conducted using SDR estimation with a dynamic intervention, timevarying confounders, and a time-to-event outcome. An ensemble of machine learning models using the super learner algorithm is used to estimate the regressions for treatment and

- 234 outcome.^{26,27} Additional details, including sensitivity analyses, an illustrated analytical file
- (eFigure 2), and code tutorial, are available in eMethods.

236 Model-first approaches

For contrast with the target trial emulation strategy, we review methodology of papers cited in Chaharom et al.'s²⁸ COVID-19 corticosteroids meta-analysis, and then analyze the data using study designs common in those papers. The data source and outcome are the same as the above target trial. Modifications to the cohort, confounders, and treatment definitions to accommodate the model-first approaches are outlined below.

242 **Point-treatment Cox models**

The first approach we explore is a regression for mortality with a point-treatment variable. The inclusion criteria and time zero are defined as the time of meeting hypoxia criteria, which is the intended indication for corticosteroids. A study design using this approach entails several choices, including defining a range of time relative to inclusion criteria for a patient to be considered "treated". Once this range is determined, researchers must decide how to handle patients treated before the inclusion time begins or after the treatment interval ends, as well as those who experience the outcome within the treatment interval.

We fit Cox models using data sets obtained from various design choices, summarized in Table 1. Baseline confounders and time-dependent confounders from day zero are included as adjustment variables. The exponentiated coefficient for corticosteroids is interpreted as the hazard ratio for corticosteroid exposure within the defined treatment window for moderate-tosevere COVID-19 patients.

These point-treatment estimates apply only to the hypoxic population. They are different from the effects in the target trial emulation, which apply to the population of hospitalized patients. These effects are the closest possible analog we can obtain within a model-first framework using a point-treatment.

259 Time-varying Cox models

In the second model-first approach, we fit a time-varying Cox model for time to mortality up to 28 days from the day of hospitalization. This model uses the entire cohort and contains baseline and time-dependent confounders, as well as daily corticosteroid administration. The coefficient for corticosteroids is exponentiated and used as an estimate of the hazard ratio for corticosteroids on mortality in hospitalized COVID-19 patients.

265 **RCT benchmark**

Several RCTs have established the effectiveness of corticosteroids in the treatment of moderateto-severe COVID-19 patients.²⁹⁻³¹ The WHO performed a meta-analysis of seven such RCTs and
estimated the OR of mortality to be 0.66 (95% CI 0.53-0.82).¹⁴ We use this estimate, as well as
supporting evidence from other RCT meta-analyses^{28,32} to benchmark our results. A discussion of
assumptions for benchmarking, along with comparisons of our target trial study design,
population, and treatment arms to the benchmark RCTs (eTables 1-3), is provided in the
Appendix.

273 **Results**

274 **Target trial emulation**

- 275 In the target trial emulation analysis, all 3,298 patients who were admitted to the hospital are
- analyzed. Table 2 and eTable 4 display characteristics of the cohort, and eTable 5 describes the
- 277 informative measurement process. There were 1,690 patients who reached severe hypoxia and
- 423 patients who received corticosteroids at any point during follow-up. 699 patients died before
- 279 28 days.
- 280 The estimated mortality rate under our no corticosteroids regime is 32.2% (95% CI 30.9-
- 281 33.5). The estimated mortality rate under our corticosteroids regime is 25.7% (24.5-26.9). This
- yields an estimated mortality reduction of 6.5% (5.7-7.4) if this policy had been implemented.
- 283 Sensitivity analyses (see Appendix) yield near-identical results.

284 Model-first approaches

In the subset of patients who met severe hypoxia, 72 patients received corticosteroids within one day of hypoxia and 191 patients received corticosteroids within 5 days of hypoxia. There were 18 and 451 patients who died within one and five days of hypoxia without receiving corticosteroids, respectively.

Model A, which defined corticosteroid exposure as anytime during hospitalization, yielded an HR of 0.50 (0.41-0.62). Models B-I, which placed either a one- or five-day limit on

- 291 corticosteroids treatment from the time of hypoxia, yielded mostly non-significant HRs in both
- directions (B: 0.95 (0.66-1.37), C: 0.92 (0.63-1.33), D: 0.89 (0.56-1.41), E: 0.66 (0.41-1.04), G:
- 293 1.05 (0.77-1.45), H: 1.04 (0.75-1.45)). The exception to this was Model I, which excluded

patients who died before five days and estimated the HR to be 0.63 (0.48-0.83). Model F also
reached statistical significance, 0.77 (0.60-0.99), and was the result of a 5-day treatment window
with no exclusion or censoring variations. The time-varying Cox model yielded an HR of 1.08
(0.80-1.47). Figure 3 summarizes the model-first results.

298 **Discussion**

299 Our research illustrates how a question-first approach can aid in devising an optimal design and 300 choice of estimation procedure for an analysis of observational data. We show that using the 301 target trial framework succeeds in recovering the benchmark causal effect obtained in RCTs. Our 302 estimate that corticosteroids would reduce overall 28-day mortality in a hospitalized cohort is 303 equivalent to an OR of 0.73 (0.68-.74), which is qualitatively identical to the WHO's estimate of 304 0.66 (0.53-0.82). Our study design allowed us to conceptualize a meaningful intervention, i.e., 305 randomize patients at hospitalization but do not give corticosteroids unless the patient becomes 306 severely hypoxic. Our analysis plan enabled us to flexibly adjust for a large number of potential 307 time-dependent confounders.

In contrast, the majority of the model-first approaches could not recover the RCT benchmark using the same data source. This finding aligns with other corticosteroids research; a recent metaanalysis containing observational analyses on over 18,000 patients found no overall effect for corticosteroids on mortality (OR 1.12, (0.83–1.50)).²⁸ The task of creating reliable evidence from complex longitudinal data is not an easy one, and many of these studies suffer from flawed designs.

We found most studies in the current observational corticosteroids literature allowed the
"treated" group to receive corticosteroids anytime during hospitalization.³³⁻³⁵ This is problematic

316 because it introduces immortal time and biases results towards a protective effect of corticosteroids.³⁵ A few studies did limit the treatment time frame in an effort to diminish 317 318 immortal time bias. The "grace period" for treatment was handled in various ways, e.g. excluding patients who die prior to a time window after inclusion criteria,³⁷ or excluding patients who 319 receive treatment after the treatment window ends.^{38,39} Both exclusions may lead to bias and 320 spurious associations.¹ An alternative to exclusion is censoring patients at their time of receiving 321 322 treatment if that time is after the treatment window passes, however, Cox regression cannot 323 handle time-dependent censoring.¹ 324 In addition to these issues, it is often unclear in the current literature how patients who receive corticosteroids prior to meeting inclusion criteria are handled in the analysis.^{33-35,40} A 325 326 related issue is that corticosteroids can affect severity of illness. All of the point-treatment studies are thus subject to collider bias by subsetting to severely ill patients.⁴¹ While the time-varying 327 328 Cox approach does not suffer from the same time-alignment biases as the point-treatment design, it cannot properly account for time-dependent confounders.¹ These biases appear in our model-329 330 first results; the study designs which result in a statistically significant protective effect of 331 corticosteroids suffer from extreme immortal time bias through undefined or extended treatment 332 time windows (A,F,I).

333

334 Limitations

First, while the pre-RCT study time frame is ideal for natural experimentation and the estimation of causal effects, it includes surge conditions and rapidly changing clinical practice, challenging the assumptions needed for transportability and benchmarking. Second, we cannot rule out unmeasured confounding in the treatment, censoring, or outcome mechanisms. Specifically, the different discharge pathways (home, nursing home, etc.) may be associated to unmeasured

340	patient characteristics and lead to very different outcomes. Third, we did not have the data to
341	look at individual corticosteroid types, making comparisons to a specific RCT impossible.
342	Fourth, the binning of our data into 24-hour intervals may induce issues related to the correct
343	time-ordering of events (see Appendix).
344	
345	Conclusions
346	This study serves as an example in which the current standard for clinical research methods
347	fails to recover the correct treatment effect where a modern causal inference method succeeds.
348	Using observational data to guide clinical practice is possible but relies on the use of
349	contemporary statistical and epidemiological principles. We hope this study and accompanying
350	technical guide encourages adoption of similar innovative techniques into study designs and
351	statistical analyses for observational medical research.
352	
353	
354	
355	

356 Acknowledgements

357	The authors thank all of the healthcare workers who courageously expanded their roles during the
358	pandemic's surge conditions. This work was made possible through data provided by the Cornell
359	COVID-19 Registry, led by Parag G. Goyal, M.D., Justin Choi, M.D., Laura Pinheiro, Ph.D., and
360	Monika Safford, M.D., of Weill Cornell Medicine. The authors would like to acknowledge the
361	chart abstractors, which included a team of Weill Cornell Medicine medical students and
362	NewYork-Presbyterian/Weill Cornell Medical Center house staff. The authors also thank the
363	contributions to this work of the Architecture for Research Computing in Health team.
364	
365	Author contributions: Katherine L. Hoffman, M.S. had full access to all the data in the study
366	and takes responsibility for the integrity of the data and the accuracy of the data analysis.
367	Conflict of Interest Disclosures: Dr. Edward Schenck is supported by NHLBI HL151876 and
368	reports consulting for Axle Informatics regarding Coronavirus vaccine clinical trial through
369	NIAID and receiving honoraria from American Thoracic Society outside of the current work. Dr.
370	Michael Satlin is supported by research grants from Allergan, Merck, BioFire Diagnostics, and
371	SNIPRBiome and reports consulting payments from Shionogi outside of the current work.

Funding/Support: This study did not receive any funding.

373

375 References

- 376 [1] Robins JM Hernán MA. *Causal Inference: What If.* Boca Raton: Chapman & Hall; 2020.
- 377 [2] Miguel A. Hernán. Methods of public health research strengthening causal inference
 378 from observational data. *New England Journal of Medicine*. 2021; 385(15):1345–1348. doi:
 379 10.1056/NEJMp2113319. URL https://doi.org/10.1056/NEJMp2113319. PMID: 34596980.
- Steven S. Henley, Richard M. Golden, and T. Michael Kashner. Statistical modeling
 methods: challenges and strategies. *Biostatistics & Epidemiology*. 2020;4(1):105–139. doi:
 10.1080/24709360.2019.1618653. URL https://doi.org/10.1080/24709360.2019.1618653.
- Mohammad Ali Mansournia, Mahyar Etminan, Goodarz Danaei, Jay S Kaufman, and Gary
 Collins. Handling time varying confounding in observational research. *BMJ*. 2017;359.
 ISSN 0959-8138. doi: 10.1136/bmj.j4587. URL https://www.bmj.com/content/359/
 bmj.j4587.
- Leo Breiman. Statistical modeling: The two cultures (with comments and a rejoinder by the author). *Statistical science*. 2001;16(3):199–231.
- 389 [6] Miguel A. Hernán. The Hazards of Hazard Ratios. *Epidemiology*. 2010;21(1):13–15, 01.
 390 doi: 10.1097/EDE.0b013e3181c1ea43.
- 391 [7] Mats J. Stensrud and Miguel A. Hernán. Why Test for Proportional Hazards? *JAMA*. 2020;
 323 (14):1401–1402, 04. ISSN 0098-7484. doi: 10.1001/jama.2020.1267. URL https:
 393 //doi.org/10.1001/jama.2020.1267.
- 394 [8] Daniel Westreich and Sander Greenland. The Table 2 Fallacy: Presenting and Interpreting
 395 Confounder and Modifier Coefficients. *American Journal of Epidemiology*.
 396 2013;177(4):292–298, 01. ISSN 0002-9262. doi: 10.1093/aje/kws412. URL
 397 https://doi.org/10.1093/aje/kws412.
- 398 [9] Gary Smith. Step away from stepwise. *Journal of Big Data*. 2018; 5(1):1–12.
 399 https://doi.org/10.1186/s40537-018-0143-6
- 400 [10] Miguel A. Hernán and James M. Robins. Using Big Data to Emulate a Target Trial When a
 401 Randomized Trial Is Not Available. *American Journal of Epidemiology*. 2016;183(8):758–
 402 764, 03. ISSN 0002-9262. doi: 10.1093/aje/kwv254. URL https://doi.org/10.1093/
 403 aje/kwv254.
- 404 [11] Maya L. Petersen and Mark J. van der Laan. Causal models and learning from data:
 405 Integrating causal modeling and statistical estimation. *Epidemiology*. 2014;25(3):418–426.
 406 ISSN 10443983. URL http://www.jstor.org/stable/24759134.
- 407 [12] Jeremy A Labrecque and Sonja A Swanson. Target trial emulation: teaching epidemiology
 408 and beyond. *European journal of epidemiology*. 2017;32(6):473–475.

- 409 [13] Miguel A. Hernán, Brian C. Sauer, Sonia Hernández-Díaz, Robert Platt, and Ian Shrier.
- 410 Specifying a target trial prevents immortal time bias and other self-inflicted injuries in
- 411 observational analyses. *Journal of Clinical Epidemiology*. 2016;79:70–75. ISSN 0895-
- 412 4356. doi: https://doi.org/10.1016/j.jclinepi.2016.04.014. URL
- 413 https://www.sciencedirect.com/ science/article/pii/S0895435616301366.
- 414 [14] Jonathan AC Sterne, Srinivas Murthy, Janet V Diaz, Arthur S Slutsky, Jesús Villar, Derek
- 415 C Angus, et al. Association between administration of systemic corticosteroids and
- 416 mortality among critically ill patients with covid-19: a meta-analysis. *Jama*. .
 417 2020;324(13):1330–1341.
- 418 [15] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE
 419 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology
 420 (STROBE)statement: guidelines for reporting observational studies.
- 421 *J Clin Epidemiol.* 2008 Apr;61(4):344-9. PMID: 18313558
- 422 [16] Steroid conversion calculator. URL https://www.mdcalc.com/ steroid423 conversion-calculator. Accessed May 10, 2020.
- 424 [17] Parag Goyal, Justin J Choi, Laura C Pinheiro, Edward J Schenck, Ruijun Chen, Assem
 425 Jabri, et al. Clinical characteristics of covid-19 in new york city. *New England Journal of*426 *Medicine*. 2020;382(24): 2372–2374.
- [18] Edward J Schenck, Katherine L Hoffman, Marika Cusick, Joseph Kabariti, Evan T Sholle,
 and Thomas R Campion Jr. Critical care database for advanced research (cedar): An
 automated method to support intensive care units with electronic health record data. *Journal of Biomedical Informatics*. 2021;118:103789.
- 431 [19] Bibhas Chakraborty and EE Moodie. Statistical methods for dynamic treatment regimes.
 432 *Springer-Verlag. 2013. doi*, 10:978–1.
- 433 [20] James Robins. A new approach to causal inference in mortality studies with a sustained
 434 exposure period—application to control of the healthy worker survivor effect.
- 435 *Mathematical Modelling*. 1986;7(9):1393–1512. ISSN 0270-0255. doi:
- 436 https://doi.org/10.1016/ 0270-0255(86)90088-6. URL
- 437 https://www.sciencedirect.com/science/article/ pii/0270025586900886.
- 438 [21] Alexander R Luedtke, Oleg Sofrygin, Mark J van der Laan, and Marco Carone. Sequential
 439 double robustness in right-censored longitudinal models. *arXiv preprint arXiv*.
- 440 2017;1705.02459.
- 441 [22] Iván Díaz, Nicholas Williams, Katherine L. Hoffman, and Edward J. Schenck.
- 442 Nonparametric causal effects based on longitudinal modified treatment policies. *Journal of the American Statistical Association*. 2021;0(0):1–16. doi:
- 444 10.1080/01621459.2021.1955691. URL https://doi.org/10.1080/01621459.2021.1955691.

[23] Mark J. van der Laan and Sherri Rose. Targeted Learning in Data Science: Causal

445

446 Inference for Complex Longitudinal Studies. Springer Publishing Company, Incorporated, 1st edition, 2018. ISBN 3319653032. 447 448 [24] Victor Chernozhukov, Denis Chetverikov, Mert Demirer, Esther Duflo, Christian Hansen, Whitney Newey, et al. Double/debiased machine learning for treatment and structural 449 450 parameters. The Econometrics Journal. 2018;21(1):C1-C68, 01. ISSN 1368-4221. doi: 451 10.1111/ectj.12097. URL https://doi.org/10.1111/ectj.12097. 452 [25] T. A. Gerds and M. Schumacher. On functional misspecification of covariates in the Cox 453 regression model. Biometrika. 2001;88(2):572–580, 06. ISSN 0006-3444. doi: 10.1093/ 454 biomet/88.2.572. URL https://doi.org/10.1093/biomet/88.2.572. 455 [26] Leo Breiman. Stacked regressions. Machine learning. 1996;24(1):49-64. 456 [27] Mark J. van der Laan, Eric C Polley, and Alan E. Hubbard. Super learner. Statistical 457 Applications in Genetics and Molecular Biology. 2007;6(1). doi: doi:10.2202/1544-458 6115.1309. URL https://doi.org/10.2202/1544-6115.1309. 459 [28] Faegheh Ebrahimi Chaharom, Leili Pourafkari, Ali Asghar Ebrahimi Chaharom, and Nader 460 D Nader. Effects of corticosteroids on covid-19 patients: A systematic review and meta-461 analysis on clinical outcomes. Pulmonary pharmacology & therapeutics, 2021;page 102-107. 462 463 [29] Bruno Martins Tomazini, Israel Silva Maia, Flavia Regina Bueno, Maria Vitoria Aparecida 464 Oliveira Silva, Franca Pellison Baldassare, et al. Covid-19-associated ards treated with 465 dexamethasone (codex): study design and rationale for a randomized trial. Revista Brasileira de terapia intensive. 2020;32:354–362. 466 467 [30] Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Zohre Naderi, Ahmadreza 468 Jamshidi, Shayan Mostafaei, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe covid-19 patients: results from a randomised controlled clinical trial. 469 470 European Respiratory Journal. 2020;56(6). 471 [31] Luis Corral-Gudino, Alberto Bahamonde, Francisco Arnaiz-Revillas, Julia Gómez-472 Barquero, Jesica Abadía-Otero, Carmen García-Ibarbia, et al. Methylprednisolone in adults hospitalized with covid-19 pneumonia. Wiener klinische Wochenschrift. 2021;133(7):303-473 474 311. [32] Carina Wagner, Mirko Griesel, Agata Mikolajewska, Anika Mueller, Monika Nothacker, 475 476 Karoline Kley, et al. Systemic corticosteroids for the treatment of covid-19. Cochrane 477 Database of Systematic Reviews. 2021;(8). 478 [33] Ana Fernández-Cruz, Belén Ruiz-Antorán, Ana Muñoz-Gómez, Aránzazu Sancho-López, 479 Patricia Mills-Sánchez, Gustavo Adolfo Centeno-Soto, et al. A retrospective con-' trolled 480 cohort study of the impact of glucocorticoid treatment in sars-cov-2 infection mortality. 481 Antimicrobial agents and chemotherapy, 2020;64(9):e01168–20.

482 [34] Brian C Nelson, Justin Laracy, Sherif Shoucri, Donald Dietz, Jason Zucker, Nina Patel, et 483 al. Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with covid-19. Clinical Infectious Diseases. 2021;72(9):e367-e372. 484 [35] Jiao Liu, Sheng Zhang, Xuan Dong, Zhongyi Li, Qianghong Xu, Huibin Feng, et al. 485 486 Corticosteroid treatment in severe covid-19 patients with acute respiratory distress 487 syndrome. The Journal of clinical investigation. 2020;130(12):6417–6428. [36] Linda E Levesque, James A Hanley, Abbas Kezouh, and Samy Suissa. Problem of immortal 488 489 time bias in cohort studies: example using statins for preventing progression of diabetes. 490 Bmj. 2010;340. 491 [37] Michele Bartoletti, Lorenzo Marconi, Luigia Scudeller, Livia Pancaldi, Sara Tedeschi, 492 Maddalena Giannella, et al. Efficacy of corticosteroid treatment for hospitalized patients 493 with severe covid-19: a multicentre study. Clinical Microbiology and Infection. 494 2021;27(1):105-111. [38] Jesús Rodríguez-Baño, Jerónimo Pachón, Jordi Carratalá, Pablo Rvan, Inmaculada Jarrín, 495 496 María Yllescas, et al. Treatment with tocilizumab or corticosteroids for covid-19 patients 497 with hyperinflammatory state: a multicentre cohort study (sam-covid-19). Clinical 498 Microbiology and Infectio. 2021;27(2):244–252. 499 500 [39] Ivan Cusacovich, Alvaro Aparisi, Miguel Marcos, Cristina Ybarra-Falcon, Carolina 501 Iglesias-Echevarria, et al. Corticosteroid pulses for hospitalized patients with covid-19: 502 effects on mortality. Mediators of inflammation, 2021. 503 [40] Cecilia Tortajada, Enrique Colomer, Juan C Andreu-Ballester, Ana Esparcia, Carmina 504 Oltra, and Juan Flores. Corticosteroids for covid-19 patients requiring oxygen support? yes, but not for everyone: effect of corticosteroids on mortality and intensive care unit admission 505

506 in patients with covid-19 according to patients' oxygen requirements. *Journal of Medical*507 *Virology*. 2021;93(3):1817–1823.

- [41] Gareth J Griffith, Tim T Morris, Matthew J Tudball, Annie Herbert, Giulia Mancano,
 Lindsey Pike, et al. Collider bias undermines our understanding of covid-19 disease risk
 and severity. *Nature communications*. 2020;11(1):1–12.
- 511
- 512

513 Figure Captions

514

515	Figure 1. Illustrated example of two patients under the two hypothetical treatment regimes of our
516	target trial emulation. Patient A reaches severe hypoxia criteria at study day 2 and is followed the
517	entire study duration. Patient B never reaches severe hypoxia criteria and is lost to follow up
518	after five study days. Under the dynamic corticosteroids regime (Intervention #1), Patient A
519	receives 6 days of corticosteroids, and under Intervention #2 they receive no corticosteroids.
520	Patient B does not receive corticosteroids under either treatment regime, however, in both
521	hypothetical worlds they are observed for the entire study duration.
522	
523	Figure 2. Illustrative Directed Acyclic Graph (DAG) showing the relationship between
524	confounders L_t , corticosteroid exposure A_t , and mortality Y_t . Baseline confounders are included in
525	L_0 . For simplicity, loss-to-follow-up nodes are not shown. Abbreviations: BMI = Body Mass
526	Index, BUN = Blood Urea Nitrogen, ACE/ARBs = Angiotensin-converting enzyme and
527	Angiotensin receptor blockers.
528	

Figure 3. Forest plot of model-first results. Study designs A-J correspond to Table 1'sspecifications.

532 Tables

Model	Study Design				
A	Corticosteroid exposure defined as anytime during the course of hospitalization. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.				
B	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.				
C	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids after the time window are included in the control group.				
D	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the time window are included in the control group.				
E	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the one-day time window passes are censored at the time of corticosteroids receipt.				
F	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.				
G	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids after the time window are included in the control group.				
Н	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the time window are included in the control group.				
I	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the one-day time window passes are censored at the time of corticosteroids receipt.				
J	Corticosteroid exposure is allowed to be a time-varying covariate beginning at the time of hospitalization.				

Table 1: Study design specifications for the model-first approaches.

534

- 536
- 537

Table 2. Demographics and outcome for study cohort, overall and stratified by any corticosteroidexposure.

Characteristic ^a	Overall [N=3,298]	Corticosteroid Never [N=2,875]	Corticosteroids Ever [N=423]
Age	65 (53, 77)	65 (52, 77)	67 (58, 75)
Sex			
Female	1,328 (40%)	1,178 (41%)	150 (35%)
Male	1,970 (60%)	1,697 (59%)	273 (65%)
Race ^b			
Asian	602 (18%)	517 (18%)	85 (20%)
Black	399 (12%)	352 (12%)	47 (11%)
White	938 (28%)	818 (28%)	120 (28%)
Other	1,141 (35%)	1,009 (35%)	132 (31%)
Unknown or declined	218 (6.6%)	179 (6.2%)	39 (9.2%)
Ethnicity			
Hispanic or Latinx	1,117 (34%)	994 (35%)	123 (29%)
Non-Hispanic or Latinx	1,585 (48%)	1,388 (48%)	197 (47%)
Unknown or declined	596 (18%)	493 (17%)	103 (24%)
BMI ^c	27 (23, 31)	27 (23, 31)	28 (24, 32)
Home supplemental oxygen	312 (9.5%)	286 (9.9%)	26 (6.1%)
Coronary Artery Disease	460 (14%)	402 (14%)	58 (14%)

Diabetes Mellitus	1,033 (31%)	891 (31%)	142 (34%)
Hypertension	1,780 (54%)	1,544 (54%)	236 (56%)
Cerebral Vascular Event	225 (6.8%)	193 (6.7%)	32 (7.6%)
Cirrhosis	35 (1.1%)	30 (1.0%)	5 (1.2%)
CKD/ESRD	159 (4.8%)	146 (5.1%)	13 (3.1%)
Asthma	180 (5.5%)	145 (5.0%)	35 (8.3%)
COPD	134 (4.1%)	100 (3.5%)	34 (8.0%)
Active cancer	136 (4.1%)	118 (4.1%)	18 (4.3%)
Immunosuppressed	51 (1.5%)	44 (1.5%)	7 (1.7%)
ILD	5 (0.2%)	3 (0.1%)	2 (0.5%)
HIV	35 (1.1%)	33 (1.1%)	2 (0.5%)
Active smoker	104 (3.2%)	93 (3.2%)	11 (2.6%)
Former smoker	543 (16%)	442 (15%)	101 (24%)
<i>Outcome:</i> 28-day mortality	699 (21%)	574 (20%)	125 (30%)

^aAll continuous variables are reported as median (interquartile range) and categorical variables are n (%). Abbreviations: BMI=Body Mass Index, CKD=Chronic Kidney Disease, ESRD=End Stage Renal Disease, COPD=Chronic Obstructive Pulmonary Disease, ILD=Interstitial Lung Disease, HIV=Human Immunodeficiency Virus. ^bOther race category includes American Indian or Alaskan Native, Pacific Islander, multiracial, or a patient response of "some other race". ^c190 (5.8 %) patients did not have BMI data available.

540





L: Confounders

Baseline - age, sex, race, ethnicity, BMI, comorbiditi (coronary artery disease, cerebral vascular event, hypertension, Diabetes Mellitus, cirrhosis, Chronic Obstructive Pulmonary Disease, active cancer, asthe interstitual lung disease, chronic kidney disease, immunosuppression, Human Immunodeficiency Vir infection, home oxygen use), mode of respiratory support within 3 hours of hospital admission, and hospital admission location.

Time-dependent - heart rate, pulse oximetry percentage, respiratory rate, temperature, systolic at diastolic blood pressure, BUN-creatinine ratio, creatinine, neutrophilis, lymphocytes, platelets, bilit blood glucose, D-dimers, C-reactive, protein, Activate Partial Thromboplastin time, prothrombin time, arte partial pressure of oxygen, and arterial partial press of carbon dioxide, mode of respiratory support, vasopressors, diuretics, ACE/ARBs, hydroxychloroq and tocilizumab.



